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To the editor: Viral diseases are among the leading causes of
morbidity and mortality in the world.1 A novel coronavirus,
designated as COVID-19, recently emerged in Wuhan, China,
at the end of 2019. As of March 5, 2020, there are >95,000
reported cases of COVID-19 and >3,000 deaths wordwide.2
Given the race against time, identifying drug treatment options as soon as possible is critical to adequately respond to
the COVID-19 outbreak.3
The “one drug, multiple viruses” paradigm came with the
discovery of broad-spectrum antiviral agents, small molecules
that inhibit a wide range of human viruses,1 and is even more
pertinent today with outbreaks of Ebola, Zika, Dengue,
inﬂuenza, and other viral infections, especially COVID-19.
Because COVID-19 is 75% to 80% identical to the severe acute
respiratory syndrome–CoV and even more closely related to
several bat coronaviruses,4 potential treatment options against

this emerging virus include as lopinavir/ritonavir, nucleoside
analogues, neuraminidase inhibitors, remdesivir, fusion peptide (EK1), abidol, RNA synthesis inhibitors (such as tenofovir
disoproxil fumarate [TDF], lamivudine [3TC]), interferon-a,
and Chinese traditional medicine, such Shufengjiedu capsules
and Lianhuaqingwen capsules, are. However, the efﬁcacy and
safety of these drugs for COVID-19 require conﬁrmation by
clinical experiments.3
Chronic kidney disease (CKD) is frequently encountered
in the general population and is a risk for increased viral
morbidity. According to the U.S. Centers for Disease Control
and Prevention, approximately 15% of U.S. adults (37
million people) are estimated to have CKD.5 During the ﬁrst
2 months of the current outbreak in China, CKD was reported in 4.3% of the Chinese patients infected with
COVID-19 who had severe presentation.6 End-stage kidney
disease patients are a highly susceptible group with an
infection rate of 16%, which exceeds that observed in other
populations.7
In the context of the epidemic or pandemic of COVID-19,
these drugs will be prescribed to patients with CKD and/or

Table 1 | Drug treatment options for COVID-19: potential kidney damage and dosage adjustment in CKD patients
COVID-19 status
Nucleoside analogs
Favipiravir
Remdesivir
Galidesivir
Azvudine
Ribavirin (in combination)

Phase II
Phase III
Animal
Phase II
Phase II

Neuraminidase inhibitors
Oseltamivir (in combination)

Fusion peptide inhibitor
EK1
HIV protease inhibitor
Lopinavir/ritonavir
Danoprevir (in combination)
Darunavir þ cobicistat
Membrane fusion inhibitor
Umifenovir
Aminoquinoline family
Chloroquine
Hydroxychloroquine

Immunotherapy
Camrelizumab

Dosage according to glomerular
ﬁltration rate

Renal adverse events

Not availablea

Not reported
Potential mitochondrial toxicity

Dosage adjustment according to standard
recommendation
Drug may be administered regardless of hemodialysis
schedule

Not reported
Hyperuricemia due to hemolytic
anemia

Phase IV

Dosage adjustment according to standard
recommendation
Drug should be administered after dialysis session to
avoid drug loss

Not reported

Cell culture

—

—

Phase IV/III

Drug should be administered at normal dosage and
regardless of hemodialysis schedule
Not availablea
Drug may be administered at normal dosage and
regardless of hemodialysis schedule

Reversible AKI
Not reported
Nephrolithiasis
False creatinine level increase

Phase IV

Not availablea

Not reported

Phase IV

Dosage adjustment according to standard
recommendation
Drug should be administered after session on
hemodialysis days

Renal lipidosis mimicking Fabry
disease
Renal lipidosis mimicking Fabry
disease
False proteinuria

Not availablea

Not yet reported
Potential PDL-1 ligand-like renal
toxicity

Phase IV
Phase II/III

Phase III

Phase II
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Table 1 | (Continued) Drug treatment options for COVID-19: potential kidney damage and dosage adjustment in CKD patients

Monoclonal antibodies
Adalimumab

Tocilizumab
Bevacizumab
IFX-1 Anti C5a
Leronlimab
REGN-3048, REGN-3051
VelocImmune (Regeneron
Technology, Tarrytown, NY)
Others
Tenofovir alafenamide
Thalidomide
Ig

COVID-19 status

Dosage according to glomerular
ﬁltration rate

Phase IV

Drug should be administered at normal dosagea

Phase IV
Phase II/III
Phase II
Phase II
Phase I
Phase I

Phase IV
Phase II
Phase II/III

Pirfenidone
Tranilast
Fingolimod
Leﬂunomide

Phase III
Phase IV
Phase II
Phase III

Artemisinin piperaquine

Phase IV

Drug should be administered at normal dosage and
regardless of hemodialysis schedule
Not availablea

Dosage adjustment according to standard
recommendation
Drug should be administered after dialysis session
Drug should be administered at normal dosage
In the absence of hemodialysis clearance data, drug
should be administered after session on hemodialysis
days
Not availablea
Drug should be administered at normal dosage and
regardless of hemodialysis schedule
Not availablea

Renal adverse events
Autoimmune GN (MN, IgA, lupus,
ANCA vasculitis); granulomatous
AIN
Not reported
HT, proteinuria, TMA, GN, IN
Not reported

AKI; proximal renal tubular acidosis
Hyperkalemia
AKI; osmotic nephrosis

Not reported
Not reported
TMA
Anti-GBM GN; HT; tubular renal
acidosis; TMA (in combination with
methotrexate)
AKI; fatal acute hepatorenal failure

COVID-19, novel coronavirus disease 2019; AIN, acute interstitial nephritis; AKI, acute kidney injury; ANCA, antineutrophil cytoplasmic antibody; CKD, chronic kidney disease;
GN, glomerulonephritis; GBM, glomerular basement membrane; HT, hypertension; IN, interstitial nephritis; MN, membranous nephropathy; PDL-1, programmed death ligand 1;
TMA, thrombotic microangiopathy.
a
In the absence of hemodialysis clearance data, drug should be administered after session on hemodialysis days.

end-stage kidney disease. Clinicians should thus be aware of
the potential dosage adjustments and renal adverse events of
those drugs in this patient group (Table 1).
Through this letter, we are not advocating any speciﬁc
therapy and we support the notion that any therapy requires
evaluation in a clinical trial. Furthermore, the rationale for
providing this information to nephrologists is that we are
likely to see off-label use of these drugs despite the absence of
data, and we will need to provide input as to how the dosing
should be modiﬁed in our patients with severely impaired
kidney function.
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